Literature DB >> 12369228

Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.

Fujian Song1, James Raftery, Paul Aveyard, Chris Hyde, Pelham Barton, Nerys Woolacott.   

Abstract

To evaluate the relative cost-effectiveness of nicotine replacement therapy (NRT) and bupropion SR for smoking cessation, the authors reviewed published studies and developed a decision analytic model from the UK National Health Services perspective. Irrespective of the methods or assumptions involved, the results of published studies consistently indicated that NRT for smoking cessation is cost-effective. No published studies have evaluated the relative cost-effectiveness of bupropion SR for smoking cessation. The results of the decision analyses indicated that, as compared with advice or counseling alone, the incremental cost per life-years saved is about $1,441-$3,455 for NRT, $920-$2,150 for bupropion SR, and $1,282-$2,836 for NRT plus bupropion SR. The cost-effectiveness of adding NRT and bupropion SR to advice or counseling for smoking cessation is better than many other accepted health care interventions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369228     DOI: 10.1177/027298902237708

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  32 in total

1.  The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles.

Authors:  A R Gilbert; C Pinget; P Bovet; J Cornuz; C Shamlaye; F Paccaud
Journal:  Tob Control       Date:  2004-06       Impact factor: 7.552

2.  A comprehensive model for mental health tobacco recovery in new jersey.

Authors:  Jill M Williams; Mia Hanos Zimmermann; Marc L Steinberg; Kunal K Gandhi; Cris Delnevo; Michael B Steinberg; Jonathan Foulds
Journal:  Adm Policy Ment Health       Date:  2011-09

3.  Extended Self-Help for Smoking Cessation: A Randomized Controlled Trial.

Authors:  Thomas H Brandon; Vani N Simmons; Steven K Sutton; Marina Unrod; Paul T Harrell; Cathy D Meade; Benjamin M Craig; Ji-Hyun Lee; Lauren R Meltzer
Journal:  Am J Prev Med       Date:  2016-02-08       Impact factor: 5.043

4.  A research agenda for assessing the potential contribution of genomic medicine to tobacco control.

Authors:  Wayne D Hall
Journal:  Tob Control       Date:  2007-02       Impact factor: 7.552

5.  Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.

Authors:  J Cornuz; A Gilbert; C Pinget; P McDonald; K Slama; E Salto; F Paccaud
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

6.  Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.

Authors:  D F Heitjan; D A Asch; Riju Ray; Margaret Rukstalis; Freda Patterson; C Lerman
Journal:  Pharmacogenomics J       Date:  2008-03-18       Impact factor: 3.550

Review 7.  Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.

Authors:  Kristian Bolin
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

8.  Cost-effectiveness of extended cessation treatment for older smokers.

Authors:  Paul G Barnett; Wynnie Wong; Abra Jeffers; Ricardo Munoz; Gary Humfleet; Sharon Hall
Journal:  Addiction       Date:  2013-12-13       Impact factor: 6.526

9.  Abstinence Reinforcement Therapy (ART) for rural veterans: Methodology for an mHealth smoking cessation intervention.

Authors:  Sarah M Wilson; Lauren P Hair; Jeffrey S Hertzberg; Angela C Kirby; Maren K Olsen; Jennifer H Lindquist; Matthew L Maciejewski; Jean C Beckham; Patrick S Calhoun
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

10.  Effects of internet-based voucher reinforcement and a transdermal nicotine patch on cigarette smoking.

Authors:  Irene M Glenn; Jesse Dallery
Journal:  J Appl Behav Anal       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.